FDA
-
-
-
-
-
-
-
Zai Lab to present updated data on lung cancer drug at 2025 conference
-
-
-
-
-
-
-
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
-
-
-
-
-
-
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
-
-
-
-
-
-
-
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO
-
-
-
-
-
-
-
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

